Global Alpha 1 Antitrypsin Deficiency Treatment Market Insights and Forecast to 2028

Publisher Name :
Date: 12-Jan-2022
No. of pages: 110
Inquire Before Buying

Alpha 1 Antitrypsin Deficiency Treatment market is segmented by players, region (country), by Indication and by End Users. Players, stakeholders, and other participants in the global Alpha 1 Antitrypsin Deficiency Treatment market will be able to gain the upper hand as they use the report as a powerful resource. The segmental analysis focuses on revenue and forecast by Indication and by End Users for the period 2017-2028.

Segment by Indication

- Augmentation Therapy

- Cystic Fibrosis(CF)

- Non-CF Bronchiectasis(NCFB)

- Diabetes

- Other

Segment by End Users

- COPD

- Cystic Fibrosis(CF)

- Non-CF Bronchiectasis(NCFB)

- Diabetes

By Company

- Pfizer

- GlaxoSmithKline

- AstraZeneca

- Boehringer Ingelheim

- Teva Pharmaceutical Industries

- Takeda

- Baxter

- Grifols

- CSL Behring

- Kamada Ltd

- Chiesi Pharmaceuticals

- Kedrion Group

- Vertex Pharmaceuticals

- ProMetic Life Sciences

By Region

- North America

- - United States

- - Canada

- Europe

- - Germany

- - France

- - UK

- - Italy

- - Russia

- - Nordic Countries

- - Rest of Europe

- Asia-Pacific

- - China

- - Japan

- - South Korea

- - Southeast Asia

- - India

- - Australia

- - Rest of Asia

- Latin America

- - Mexico

- - Brazil

- - Rest of Latin America

- Middle East & Africa

- - Turkey

- - Saudi Arabia

- - UAE

- - Rest of MEA

Global Alpha 1 Antitrypsin Deficiency Treatment Market Insights and Forecast to 2028

Table of Contents
1 Report Business Overview
1.1 Study Scope
1.2 Market Analysis by Indication
1.2.1 Global Alpha 1 Antitrypsin Deficiency Treatment Market Size Growth Rate by Indication, 2017 VS 2021 VS 2028
1.2.2 Augmentation Therapy
1.2.3 Cystic Fibrosis(CF)
1.2.4 Non-CF Bronchiectasis(NCFB)
1.2.5 Diabetes
1.2.6 Other
1.3 Market by End Users
1.3.1 Global Alpha 1 Antitrypsin Deficiency Treatment Market Size Growth Rate by End Users, 2017 VS 2021 VS 2028
1.3.2 COPD
1.3.3 Cystic Fibrosis(CF)
1.3.4 Non-CF Bronchiectasis(NCFB)
1.3.5 Diabetes
1.4 Study Objectives
1.5 Years Considered
2 Global Growth Trends
2.1 Global Alpha 1 Antitrypsin Deficiency Treatment Market Perspective (2017-2028)
2.2 Alpha 1 Antitrypsin Deficiency Treatment Growth Trends by Region
2.2.1 Alpha 1 Antitrypsin Deficiency Treatment Market Size by Region: 2017 VS 2021 VS 2028
2.2.2 Alpha 1 Antitrypsin Deficiency Treatment Historic Market Size by Region (2017-2022)
2.2.3 Alpha 1 Antitrypsin Deficiency Treatment Forecasted Market Size by Region (2023-2028)
2.3 Alpha 1 Antitrypsin Deficiency Treatment Market Dynamics
2.3.1 Alpha 1 Antitrypsin Deficiency Treatment Industry Trends
2.3.2 Alpha 1 Antitrypsin Deficiency Treatment Market Drivers
2.3.3 Alpha 1 Antitrypsin Deficiency Treatment Market Challenges
2.3.4 Alpha 1 Antitrypsin Deficiency Treatment Market Restraints
3 Competition Landscape by Key Players
3.1 Global Top Alpha 1 Antitrypsin Deficiency Treatment Players by Revenue
3.1.1 Global Top Alpha 1 Antitrypsin Deficiency Treatment Players by Revenue (2017-2022)
3.1.2 Global Alpha 1 Antitrypsin Deficiency Treatment Revenue Market Share by Players (2017-2022)
3.2 Global Alpha 1 Antitrypsin Deficiency Treatment Market Share by Company Type (Tier 1, Tier 2, and Tier 3)
3.3 Players Covered: Ranking by Alpha 1 Antitrypsin Deficiency Treatment Revenue
3.4 Global Alpha 1 Antitrypsin Deficiency Treatment Market Concentration Ratio
3.4.1 Global Alpha 1 Antitrypsin Deficiency Treatment Market Concentration Ratio (CR5 and HHI)
3.4.2 Global Top 10 and Top 5 Companies by Alpha 1 Antitrypsin Deficiency Treatment Revenue in 2021
3.5 Alpha 1 Antitrypsin Deficiency Treatment Key Players Head office and Area Served
3.6 Key Players Alpha 1 Antitrypsin Deficiency Treatment Product Solution and Service
3.7 Date of Enter into Alpha 1 Antitrypsin Deficiency Treatment Market
3.8 Mergers & Acquisitions, Expansion Plans
4 Alpha 1 Antitrypsin Deficiency Treatment Breakdown Data by Indication
4.1 Global Alpha 1 Antitrypsin Deficiency Treatment Historic Market Size by Indication (2017-2022)
4.2 Global Alpha 1 Antitrypsin Deficiency Treatment Forecasted Market Size by Indication (2023-2028)
5 Alpha 1 Antitrypsin Deficiency Treatment Breakdown Data by End Users
5.1 Global Alpha 1 Antitrypsin Deficiency Treatment Historic Market Size by End Users (2017-2022)
5.2 Global Alpha 1 Antitrypsin Deficiency Treatment Forecasted Market Size by End Users (2023-2028)
6 North America
6.1 North America Alpha 1 Antitrypsin Deficiency Treatment Market Size (2017-2028)
6.2 North America Alpha 1 Antitrypsin Deficiency Treatment Market Size by Indication
6.2.1 North America Alpha 1 Antitrypsin Deficiency Treatment Market Size by Indication (2017-2022)
6.2.2 North America Alpha 1 Antitrypsin Deficiency Treatment Market Size by Indication (2023-2028)
6.2.3 North America Alpha 1 Antitrypsin Deficiency Treatment Market Share by Indication (2017-2028)
6.3 North America Alpha 1 Antitrypsin Deficiency Treatment Market Size by End Users
6.3.1 North America Alpha 1 Antitrypsin Deficiency Treatment Market Size by End Users (2017-2022)
6.3.2 North America Alpha 1 Antitrypsin Deficiency Treatment Market Size by End Users (2023-2028)
6.3.3 North America Alpha 1 Antitrypsin Deficiency Treatment Market Share by End Users (2017-2028)
6.4 North America Alpha 1 Antitrypsin Deficiency Treatment Market Size by Country
6.4.1 North America Alpha 1 Antitrypsin Deficiency Treatment Market Size by Country (2017-2022)
6.4.2 North America Alpha 1 Antitrypsin Deficiency Treatment Market Size by Country (2023-2028)
6.4.3 United States
6.4.4 Canada
7 Europe
7.1 Europe Alpha 1 Antitrypsin Deficiency Treatment Market Size (2017-2028)
7.2 Europe Alpha 1 Antitrypsin Deficiency Treatment Market Size by Indication
7.2.1 Europe Alpha 1 Antitrypsin Deficiency Treatment Market Size by Indication (2017-2022)
7.2.2 Europe Alpha 1 Antitrypsin Deficiency Treatment Market Size by Indication (2023-2028)
7.2.3 Europe Alpha 1 Antitrypsin Deficiency Treatment Market Share by Indication (2017-2028)
7.3 Europe Alpha 1 Antitrypsin Deficiency Treatment Market Size by End Users
7.3.1 Europe Alpha 1 Antitrypsin Deficiency Treatment Market Size by End Users (2017-2022)
7.3.2 Europe Alpha 1 Antitrypsin Deficiency Treatment Market Size by End Users (2023-2028)
7.3.3 Europe Alpha 1 Antitrypsin Deficiency Treatment Market Share by End Users (2017-2028)
7.4 Europe Alpha 1 Antitrypsin Deficiency Treatment Market Size by Country
7.4.1 Europe Alpha 1 Antitrypsin Deficiency Treatment Market Size by Country (2017-2022)
7.4.2 Europe Alpha 1 Antitrypsin Deficiency Treatment Market Size by Country (2023-2028)
7.4.3 Germany
7.4.4 France
7.4.5 U.K.
7.4.6 Italy
7.4.7 Russia
7.4.8 Nordic Countries
8 Asia-Pacific
8.1 Asia-Pacific Alpha 1 Antitrypsin Deficiency Treatment Market Size (2017-2028)
8.2 Asia-Pacific Alpha 1 Antitrypsin Deficiency Treatment Market Size by Indication
8.2.1 Asia-Pacific Alpha 1 Antitrypsin Deficiency Treatment Market Size by Indication (2017-2022)
8.2.2 Asia-Pacific Alpha 1 Antitrypsin Deficiency Treatment Market Size by Indication (2023-2028)
8.2.3 Asia-Pacific Alpha 1 Antitrypsin Deficiency Treatment Market Share by Indication (2017-2028)
8.3 Asia-Pacific Alpha 1 Antitrypsin Deficiency Treatment Market Size by End Users
8.3.1 Asia-Pacific Alpha 1 Antitrypsin Deficiency Treatment Market Size by End Users (2017-2022)
8.3.2 Asia-Pacific Alpha 1 Antitrypsin Deficiency Treatment Market Size by End Users (2023-2028)
8.3.3 Asia-Pacific Alpha 1 Antitrypsin Deficiency Treatment Market Share by End Users (2017-2028)
8.4 Asia-Pacific Alpha 1 Antitrypsin Deficiency Treatment Market Size by Region
8.4.1 Asia-Pacific Alpha 1 Antitrypsin Deficiency Treatment Market Size by Region (2017-2022)
8.4.2 Asia-Pacific Alpha 1 Antitrypsin Deficiency Treatment Market Size by Region (2023-2028)
8.4.3 China
8.4.4 Japan
8.4.5 South Korea
8.4.6 Southeast Asia
8.4.7 India
8.4.8 Australia
9 Latin America
9.1 Latin America Alpha 1 Antitrypsin Deficiency Treatment Market Size (2017-2028)
9.2 Latin America Alpha 1 Antitrypsin Deficiency Treatment Market Size by Indication
9.2.1 Latin America Alpha 1 Antitrypsin Deficiency Treatment Market Size by Indication (2017-2022)
9.2.2 Latin America Alpha 1 Antitrypsin Deficiency Treatment Market Size by Indication (2023-2028)
9.2.3 Latin America Alpha 1 Antitrypsin Deficiency Treatment Market Share by Indication (2017-2028)
9.3 Latin America Alpha 1 Antitrypsin Deficiency Treatment Market Size by End Users
9.3.1 Latin America Alpha 1 Antitrypsin Deficiency Treatment Market Size by End Users (2017-2022)
9.3.2 Latin America Alpha 1 Antitrypsin Deficiency Treatment Market Size by End Users (2023-2028)
9.3.3 Latin America Alpha 1 Antitrypsin Deficiency Treatment Market Share by End Users (2017-2028)
9.4 Latin America Alpha 1 Antitrypsin Deficiency Treatment Market Size by Country
9.4.1 Latin America Alpha 1 Antitrypsin Deficiency Treatment Market Size by Country (2017-2022)
9.4.2 Latin America Alpha 1 Antitrypsin Deficiency Treatment Market Size by Country (2023-2028)
9.4.3 Mexico
9.4.4 Brazil
10 Middle East & Africa
10.1 Middle East & Africa Alpha 1 Antitrypsin Deficiency Treatment Market Size (2017-2028)
10.2 Middle East & Africa Alpha 1 Antitrypsin Deficiency Treatment Market Size by Indication
10.2.1 Middle East & Africa Alpha 1 Antitrypsin Deficiency Treatment Market Size by Indication (2017-2022)
10.2.2 Middle East & Africa Alpha 1 Antitrypsin Deficiency Treatment Market Size by Indication (2023-2028)
10.2.3 Middle East & Africa Alpha 1 Antitrypsin Deficiency Treatment Market Share by Indication (2017-2028)
10.3 Middle East & Africa Alpha 1 Antitrypsin Deficiency Treatment Market Size by End Users
10.3.1 Middle East & Africa Alpha 1 Antitrypsin Deficiency Treatment Market Size by End Users (2017-2022)
10.3.2 Middle East & Africa Alpha 1 Antitrypsin Deficiency Treatment Market Size by End Users (2023-2028)
10.3.3 Middle East & Africa Alpha 1 Antitrypsin Deficiency Treatment Market Share by End Users (2017-2028)
10.4 Middle East & Africa Alpha 1 Antitrypsin Deficiency Treatment Market Size by Country
10.4.1 Middle East & Africa Alpha 1 Antitrypsin Deficiency Treatment Market Size by Country (2017-2022)
10.4.2 Middle East & Africa Alpha 1 Antitrypsin Deficiency Treatment Market Size by Country (2023-2028)
10.4.3 Turkey
10.4.4 Saudi Arabia
10.4.5 UAE
11 Key Players Profiles
11.1 Pfizer
11.1.1 Pfizer Company Details
11.1.2 Pfizer Business Overview
11.1.3 Pfizer Alpha 1 Antitrypsin Deficiency Treatment Introduction
11.1.4 Pfizer Revenue in Alpha 1 Antitrypsin Deficiency Treatment Business (2017-2022)
11.1.5 Pfizer Recent Developments
11.2 GlaxoSmithKline
11.2.1 GlaxoSmithKline Company Details
11.2.2 GlaxoSmithKline Business Overview
11.2.3 GlaxoSmithKline Alpha 1 Antitrypsin Deficiency Treatment Introduction
11.2.4 GlaxoSmithKline Revenue in Alpha 1 Antitrypsin Deficiency Treatment Business (2017-2022)
11.2.5 GlaxoSmithKline Recent Developments
11.3 AstraZeneca
11.3.1 AstraZeneca Company Details
11.3.2 AstraZeneca Business Overview
11.3.3 AstraZeneca Alpha 1 Antitrypsin Deficiency Treatment Introduction
11.3.4 AstraZeneca Revenue in Alpha 1 Antitrypsin Deficiency Treatment Business (2017-2022)
11.3.5 AstraZeneca Recent Developments
11.4 Boehringer Ingelheim
11.4.1 Boehringer Ingelheim Company Details
11.4.2 Boehringer Ingelheim Business Overview
11.4.3 Boehringer Ingelheim Alpha 1 Antitrypsin Deficiency Treatment Introduction
11.4.4 Boehringer Ingelheim Revenue in Alpha 1 Antitrypsin Deficiency Treatment Business (2017-2022)
11.4.5 Boehringer Ingelheim Recent Developments
11.5 Teva Pharmaceutical Industries
11.5.1 Teva Pharmaceutical Industries Company Details
11.5.2 Teva Pharmaceutical Industries Business Overview
11.5.3 Teva Pharmaceutical Industries Alpha 1 Antitrypsin Deficiency Treatment Introduction
11.5.4 Teva Pharmaceutical Industries Revenue in Alpha 1 Antitrypsin Deficiency Treatment Business (2017-2022)
11.5.5 Teva Pharmaceutical Industries Recent Developments
11.6 Takeda
11.6.1 Takeda Company Details
11.6.2 Takeda Business Overview
11.6.3 Takeda Alpha 1 Antitrypsin Deficiency Treatment Introduction
11.6.4 Takeda Revenue in Alpha 1 Antitrypsin Deficiency Treatment Business (2017-2022)
11.6.5 Takeda Recent Developments
11.7 Baxter
11.7.1 Baxter Company Details
11.7.2 Baxter Business Overview
11.7.3 Baxter Alpha 1 Antitrypsin Deficiency Treatment Introduction
11.7.4 Baxter Revenue in Alpha 1 Antitrypsin Deficiency Treatment Business (2017-2022)
11.7.5 Baxter Recent Developments
11.8 Grifols
11.8.1 Grifols Company Details
11.8.2 Grifols Business Overview
11.8.3 Grifols Alpha 1 Antitrypsin Deficiency Treatment Introduction
11.8.4 Grifols Revenue in Alpha 1 Antitrypsin Deficiency Treatment Business (2017-2022)
11.8.5 Grifols Recent Developments
11.9 CSL Behring
11.9.1 CSL Behring Company Details
11.9.2 CSL Behring Business Overview
11.9.3 CSL Behring Alpha 1 Antitrypsin Deficiency Treatment Introduction
11.9.4 CSL Behring Revenue in Alpha 1 Antitrypsin Deficiency Treatment Business (2017-2022)
11.9.5 CSL Behring Recent Developments
11.10 Kamada Ltd
11.10.1 Kamada Ltd Company Details
11.10.2 Kamada Ltd Business Overview
11.10.3 Kamada Ltd Alpha 1 Antitrypsin Deficiency Treatment Introduction
11.10.4 Kamada Ltd Revenue in Alpha 1 Antitrypsin Deficiency Treatment Business (2017-2022)
11.10.5 Kamada Ltd Recent Developments
11.11 Chiesi Pharmaceuticals
11.11.1 Chiesi Pharmaceuticals Company Details
11.11.2 Chiesi Pharmaceuticals Business Overview
11.11.3 Chiesi Pharmaceuticals Alpha 1 Antitrypsin Deficiency Treatment Introduction
11.11.4 Chiesi Pharmaceuticals Revenue in Alpha 1 Antitrypsin Deficiency Treatment Business (2017-2022)
11.11.5 Chiesi Pharmaceuticals Recent Developments
11.12 Kedrion Group
11.12.1 Kedrion Group Company Details
11.12.2 Kedrion Group Business Overview
11.12.3 Kedrion Group Alpha 1 Antitrypsin Deficiency Treatment Introduction
11.12.4 Kedrion Group Revenue in Alpha 1 Antitrypsin Deficiency Treatment Business (2017-2022)
11.12.5 Kedrion Group Recent Developments
11.13 Vertex Pharmaceuticals
11.13.1 Vertex Pharmaceuticals Company Details
11.13.2 Vertex Pharmaceuticals Business Overview
11.13.3 Vertex Pharmaceuticals Alpha 1 Antitrypsin Deficiency Treatment Introduction
11.13.4 Vertex Pharmaceuticals Revenue in Alpha 1 Antitrypsin Deficiency Treatment Business (2017-2022)
11.13.5 Vertex Pharmaceuticals Recent Developments
11.14 ProMetic Life Sciences
11.14.1 ProMetic Life Sciences Company Details
11.14.2 ProMetic Life Sciences Business Overview
11.14.3 ProMetic Life Sciences Alpha 1 Antitrypsin Deficiency Treatment Introduction
11.14.4 ProMetic Life Sciences Revenue in Alpha 1 Antitrypsin Deficiency Treatment Business (2017-2022)
11.14.5 ProMetic Life Sciences Recent Developments
12 Analyst's Viewpoints/Conclusions
13 Appendix
13.1 Research Methodology
13.1.1 Methodology/Research Approach
13.1.2 Data Source
13.2 Author Details
13.3 Disclaimer
List of Tables
Table 1. Global Alpha 1 Antitrypsin Deficiency Treatment Market Size Growth Rate by Indication (US$ Million), 2017 VS 2021 VS 2028
Table 2. Key Players of Augmentation Therapy
Table 3. Key Players of Cystic Fibrosis(CF)
Table 4. Key Players of Non-CF Bronchiectasis(NCFB)
Table 5. Key Players of Diabetes
Table 6. Key Players of Other
Table 7. Global Alpha 1 Antitrypsin Deficiency Treatment Market Size Growth Rate by End Users (US$ Million), 2017 VS 2021 VS 2028
Table 8. Global Alpha 1 Antitrypsin Deficiency Treatment Market Size by Region (US$ Million): 2017 VS 2021 VS 2028
Table 9. Global Alpha 1 Antitrypsin Deficiency Treatment Market Size by Region (2017-2022) & (US$ Million)
Table 10. Global Alpha 1 Antitrypsin Deficiency Treatment Market Share by Region (2017-2022)
Table 11. Global Alpha 1 Antitrypsin Deficiency Treatment Forecasted Market Size by Region (2023-2028) & (US$ Million)
Table 12. Global Alpha 1 Antitrypsin Deficiency Treatment Market Share by Region (2023-2028)
Table 13. Alpha 1 Antitrypsin Deficiency Treatment Market Trends
Table 14. Alpha 1 Antitrypsin Deficiency Treatment Market Drivers
Table 15. Alpha 1 Antitrypsin Deficiency Treatment Market Challenges
Table 16. Alpha 1 Antitrypsin Deficiency Treatment Market Restraints
Table 17. Global Alpha 1 Antitrypsin Deficiency Treatment Revenue by Players (2017-2022) & (US$ Million)
Table 18. Global Alpha 1 Antitrypsin Deficiency Treatment Revenue Share by Players (2017-2022)
Table 19. Global Top Alpha 1 Antitrypsin Deficiency Treatment by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Alpha 1 Antitrypsin Deficiency Treatment as of 2021)
Table 20. Ranking of Global Top Alpha 1 Antitrypsin Deficiency Treatment Companies by Revenue (US$ Million) in 2021
Table 21. Global 5 Largest Players Market Share by Alpha 1 Antitrypsin Deficiency Treatment Revenue (CR5 and HHI) & (2017-2022)
Table 22. Key Players Headquarters and Area Served
Table 23. Key Players Alpha 1 Antitrypsin Deficiency Treatment Product Solution and Service
Table 24. Date of Enter into Alpha 1 Antitrypsin Deficiency Treatment Market
Table 25. Mergers & Acquisitions, Expansion Plans
Table 26. Global Alpha 1 Antitrypsin Deficiency Treatment Market Size by Indication (2017-2022) & (US$ Million)
Table 27. Global Alpha 1 Antitrypsin Deficiency Treatment Revenue Market Share by Indication (2017-2022)
Table 28. Global Alpha 1 Antitrypsin Deficiency Treatment Forecasted Market Size by Indication (2023-2028) & (US$ Million)
Table 29. Global Alpha 1 Antitrypsin Deficiency Treatment Revenue Market Share by Indication (2023-2028)
Table 30. Global Alpha 1 Antitrypsin Deficiency Treatment Market Size by End Users (2017-2022) & (US$ Million)
Table 31. Global Alpha 1 Antitrypsin Deficiency Treatment Revenue Share by End Users (2017-2022)
Table 32. Global Alpha 1 Antitrypsin Deficiency Treatment Forecasted Market Size by End Users (2023-2028) & (US$ Million)
Table 33. Global Alpha 1 Antitrypsin Deficiency Treatment Revenue Share by End Users (2023-2028)
Table 34. North America Alpha 1 Antitrypsin Deficiency Treatment Market Size by Indication (2017-2022) & (US$ Million)
Table 35. North America Alpha 1 Antitrypsin Deficiency Treatment Market Size by Indication (2023-2028) & (US$ Million)
Table 36. North America Alpha 1 Antitrypsin Deficiency Treatment Market Size by End Users (2017-2022) & (US$ Million)
Table 37. North America Alpha 1 Antitrypsin Deficiency Treatment Market Size by End Users (2023-2028) & (US$ Million)
Table 38. North America Alpha 1 Antitrypsin Deficiency Treatment Market Size by Country (2017-2022) & (US$ Million)
Table 39. North America Alpha 1 Antitrypsin Deficiency Treatment Market Size by Country (2023-2028) & (US$ Million)
Table 40. Europe Alpha 1 Antitrypsin Deficiency Treatment Market Size by Indication (2017-2022) & (US$ Million)
Table 41. Europe Alpha 1 Antitrypsin Deficiency Treatment Market Size by Indication (2023-2028) & (US$ Million)
Table 42. Europe Alpha 1 Antitrypsin Deficiency Treatment Market Size by End Users (2017-2022) & (US$ Million)
Table 43. Europe Alpha 1 Antitrypsin Deficiency Treatment Market Size by End Users (2023-2028) & (US$ Million)
Table 44. Europe Alpha 1 Antitrypsin Deficiency Treatment Market Size by Country (2017-2022) & (US$ Million)
Table 45. Europe Alpha 1 Antitrypsin Deficiency Treatment Market Size by Country (2023-2028) & (US$ Million)
Table 46. Asia Pacific Alpha 1 Antitrypsin Deficiency Treatment Market Size by Indication (2017-2022) & (US$ Million)
Table 47. Asia Pacific Alpha 1 Antitrypsin Deficiency Treatment Market Size by Indication (2023-2028) & (US$ Million)
Table 48. Asia Pacific Alpha 1 Antitrypsin Deficiency Treatment Market Size by End Users (2017-2022) & (US$ Million)
Table 49. Asia Pacific Alpha 1 Antitrypsin Deficiency Treatment Market Size by End Users (2023-2028) & (US$ Million)
Table 50. Asia Pacific Alpha 1 Antitrypsin Deficiency Treatment Market Size by Region (2017-2022) & (US$ Million)
Table 51. Asia Pacific Alpha 1 Antitrypsin Deficiency Treatment Market Size by Region (2023-2028) & (US$ Million)
Table 52. Latin America Alpha 1 Antitrypsin Deficiency Treatment Market Size by Indication (2017-2022) & (US$ Million)
Table 53. Latin America Alpha 1 Antitrypsin Deficiency Treatment Market Size by Indication (2023-2028) & (US$ Million)
Table 54. Latin America Alpha 1 Antitrypsin Deficiency Treatment Market Size by End Users (2017-2022) & (US$ Million)
Table 55. Latin America Alpha 1 Antitrypsin Deficiency Treatment Market Size by End Users (2023-2028) & (US$ Million)
Table 56. Latin America Alpha 1 Antitrypsin Deficiency Treatment Market Size by Country (2017-2022) & (US$ Million)
Table 57. Latin America Alpha 1 Antitrypsin Deficiency Treatment Market Size by Country (2023-2028) & (US$ Million)
Table 58. Middle East and Africa Alpha 1 Antitrypsin Deficiency Treatment Market Size by Indication (2017-2022) & (US$ Million)
Table 59. Middle East and Africa Alpha 1 Antitrypsin Deficiency Treatment Market Size by Indication (2023-2028) & (US$ Million)
Table 60. Middle East and Africa Alpha 1 Antitrypsin Deficiency Treatment Market Size by End Users (2017-2022) & (US$ Million)
Table 61. Middle East and Africa Alpha 1 Antitrypsin Deficiency Treatment Market Size by End Users (2023-2028) & (US$ Million)
Table 62. Middle East and Africa Alpha 1 Antitrypsin Deficiency Treatment Market Size by Country (2017-2022) & (US$ Million)
Table 63. Middle East and Africa Alpha 1 Antitrypsin Deficiency Treatment Market Size by Country (2023-2028) & (US$ Million)
Table 64. Pfizer Company Details
Table 65. Pfizer Business Overview
Table 66. Pfizer Alpha 1 Antitrypsin Deficiency Treatment Product
Table 67. Pfizer Revenue in Alpha 1 Antitrypsin Deficiency Treatment Business (2017-2022) & (US$ Million)
Table 68. Pfizer Recent Developments
Table 69. GlaxoSmithKline Company Details
Table 70. GlaxoSmithKline Business Overview
Table 71. GlaxoSmithKline Alpha 1 Antitrypsin Deficiency Treatment Product
Table 72. GlaxoSmithKline Revenue in Alpha 1 Antitrypsin Deficiency Treatment Business (2017-2022) & (US$ Million)
Table 73. GlaxoSmithKline Recent Developments
Table 74. AstraZeneca Company Details
Table 75. AstraZeneca Business Overview
Table 76. AstraZeneca Alpha 1 Antitrypsin Deficiency Treatment Product
Table 77. AstraZeneca Revenue in Alpha 1 Antitrypsin Deficiency Treatment Business (2017-2022) & (US$ Million)
Table 78. AstraZeneca Recent Developments
Table 79. Boehringer Ingelheim Company Details
Table 80. Boehringer Ingelheim Business Overview
Table 81. Boehringer Ingelheim Alpha 1 Antitrypsin Deficiency Treatment Product
Table 82. Boehringer Ingelheim Revenue in Alpha 1 Antitrypsin Deficiency Treatment Business (2017-2022) & (US$ Million)
Table 83. Boehringer Ingelheim Recent Developments
Table 84. Teva Pharmaceutical Industries Company Details
Table 85. Teva Pharmaceutical Industries Business Overview
Table 86. Teva Pharmaceutical Industries Alpha 1 Antitrypsin Deficiency Treatment Product
Table 87. Teva Pharmaceutical Industries Revenue in Alpha 1 Antitrypsin Deficiency Treatment Business (2017-2022) & (US$ Million)
Table 88. Teva Pharmaceutical Industries Recent Developments
Table 89. Takeda Company Details
Table 90. Takeda Business Overview
Table 91. Takeda Alpha 1 Antitrypsin Deficiency Treatment Product
Table 92. Takeda Revenue in Alpha 1 Antitrypsin Deficiency Treatment Business (2017-2022) & (US$ Million)
Table 93. Takeda Recent Developments
Table 94. Baxter Company Details
Table 95. Baxter Business Overview
Table 96. Baxter Alpha 1 Antitrypsin Deficiency Treatment Product
Table 97. Baxter Revenue in Alpha 1 Antitrypsin Deficiency Treatment Business (2017-2022) & (US$ Million)
Table 98. Baxter Recent Developments
Table 99. Grifols Company Details
Table 100. Grifols Business Overview
Table 101. Grifols Alpha 1 Antitrypsin Deficiency Treatment Product
Table 102. Grifols Revenue in Alpha 1 Antitrypsin Deficiency Treatment Business (2017-2022) & (US$ Million)
Table 103. Grifols Recent Developments
Table 104. CSL Behring Company Details
Table 105. CSL Behring Business Overview
Table 106. CSL Behring Alpha 1 Antitrypsin Deficiency Treatment Product
Table 107. CSL Behring Revenue in Alpha 1 Antitrypsin Deficiency Treatment Business (2017-2022) & (US$ Million)
Table 108. CSL Behring Recent Developments
Table 109. Kamada Ltd Company Details
Table 110. Kamada Ltd Business Overview
Table 111. Kamada Ltd Alpha 1 Antitrypsin Deficiency Treatment Product
Table 112. Kamada Ltd Revenue in Alpha 1 Antitrypsin Deficiency Treatment Business (2017-2022) & (US$ Million)
Table 113. Kamada Ltd Recent Developments
Table 114. Chiesi Pharmaceuticals Company Details
Table 115. Chiesi Pharmaceuticals Business Overview
Table 116. Chiesi Pharmaceuticals Alpha 1 Antitrypsin Deficiency Treatment Product
Table 117. Chiesi Pharmaceuticals Revenue in Alpha 1 Antitrypsin Deficiency Treatment Business (2017-2022) & (US$ Million)
Table 118. Chiesi Pharmaceuticals Recent Developments
Table 119. Kedrion Group Company Details
Table 120. Kedrion Group Business Overview
Table 121. Kedrion Group Alpha 1 Antitrypsin Deficiency Treatment Product
Table 122. Kedrion Group Revenue in Alpha 1 Antitrypsin Deficiency Treatment Business (2017-2022) & (US$ Million)
Table 123. Kedrion Group Recent Developments
Table 124. Vertex Pharmaceuticals Company Details
Table 125. Vertex Pharmaceuticals Business Overview
Table 126. Vertex Pharmaceuticals Alpha 1 Antitrypsin Deficiency Treatment Product
Table 127. Vertex Pharmaceuticals Revenue in Alpha 1 Antitrypsin Deficiency Treatment Business (2017-2022) & (US$ Million)
Table 128. Vertex Pharmaceuticals Recent Developments
Table 129. ProMetic Life Sciences Company Details
Table 130. ProMetic Life Sciences Business Overview
Table 131. ProMetic Life Sciences Alpha 1 Antitrypsin Deficiency Treatment Product
Table 132. ProMetic Life Sciences Revenue in Alpha 1 Antitrypsin Deficiency Treatment Business (2017-2022) & (US$ Million)
Table 133. ProMetic Life Sciences Recent Developments
Table 134. Research Programs/Design for This Report
Table 135. Key Data Information from Secondary Sources
Table 136. Key Data Information from Primary Sources
List of Figures
Figure 1. Global Alpha 1 Antitrypsin Deficiency Treatment Market Share by Indication: 2021 VS 2028
Figure 2. Augmentation Therapy Features
Figure 3. Cystic Fibrosis(CF) Features
Figure 4. Non-CF Bronchiectasis(NCFB) Features
Figure 5. Diabetes Features
Figure 6. Other Features
Figure 7. Global Alpha 1 Antitrypsin Deficiency Treatment Market Share by End Users: 2021 VS 2028
Figure 8. COPD Case Studies
Figure 9. Cystic Fibrosis(CF) Case Studies
Figure 10. Non-CF Bronchiectasis(NCFB) Case Studies
Figure 11. Diabetes Case Studies
Figure 12. Alpha 1 Antitrypsin Deficiency Treatment Report Years Considered
Figure 13. Global Alpha 1 Antitrypsin Deficiency Treatment Market Size (US$ Million), Year-over-Year: 2017-2028
Figure 14. Global Alpha 1 Antitrypsin Deficiency Treatment Market Size, (US$ Million), 2017 VS 2021 VS 2028
Figure 15. Global Alpha 1 Antitrypsin Deficiency Treatment Market Share by Region: 2021 VS 2028
Figure 16. Global Alpha 1 Antitrypsin Deficiency Treatment Market Share by Players in 2021
Figure 17. Global Top Alpha 1 Antitrypsin Deficiency Treatment Players by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Alpha 1 Antitrypsin Deficiency Treatment as of 2021)
Figure 18. The Top 10 and 5 Players Market Share by Alpha 1 Antitrypsin Deficiency Treatment Revenue in 2021
Figure 19. North America Alpha 1 Antitrypsin Deficiency Treatment Market Size YoY (2017-2028) & (US$ Million)
Figure 20. North America Alpha 1 Antitrypsin Deficiency Treatment Market Size Market Share by Indication (2017-2028)
Figure 21. North America Alpha 1 Antitrypsin Deficiency Treatment Market Size Market Share by End Users (2017-2028)
Figure 22. North America Alpha 1 Antitrypsin Deficiency Treatment Market Size Share by Country (2017-2028)
Figure 23. United States Alpha 1 Antitrypsin Deficiency Treatment Market Size YoY Growth (2017-2028) & (US$ Million)
Figure 24. Canada Alpha 1 Antitrypsin Deficiency Treatment Market Size YoY Growth (2017-2028) & (US$ Million)
Figure 25. Europe Alpha 1 Antitrypsin Deficiency Treatment Market Size YoY (2017-2028) & (US$ Million)
Figure 26. Europe Alpha 1 Antitrypsin Deficiency Treatment Market Size Market Share by Indication (2017-2028)
Figure 27. Europe Alpha 1 Antitrypsin Deficiency Treatment Market Size Market Share by End Users (2017-2028)
Figure 28. Europe Alpha 1 Antitrypsin Deficiency Treatment Market Size Share by Country (2017-2028)
Figure 29. Germany Alpha 1 Antitrypsin Deficiency Treatment Market Size YoY Growth (2017-2028) & (US$ Million)
Figure 30. France Alpha 1 Antitrypsin Deficiency Treatment Market Size YoY Growth (2017-2028) & (US$ Million)
Figure 31. U.K. Alpha 1 Antitrypsin Deficiency Treatment Market Size YoY Growth (2017-2028) & (US$ Million)
Figure 32. Italy Alpha 1 Antitrypsin Deficiency Treatment Market Size YoY Growth (2017-2028) & (US$ Million)
Figure 33. Russia Alpha 1 Antitrypsin Deficiency Treatment Market Size YoY Growth (2017-2028) & (US$ Million)
Figure 34. Nordic Countries Alpha 1 Antitrypsin Deficiency Treatment Market Size YoY Growth (2017-2028) & (US$ Million)
Figure 35. Asia-Pacific Alpha 1 Antitrypsin Deficiency Treatment Market Size YoY (2017-2028) & (US$ Million)
Figure 36. Asia Pacific Alpha 1 Antitrypsin Deficiency Treatment Market Size Market Share by Indication (2017-2028)
Figure 37. Asia Pacific Alpha 1 Antitrypsin Deficiency Treatment Market Size Market Share by End Users (2017-2028)
Figure 38. Asia Pacific Alpha 1 Antitrypsin Deficiency Treatment Market Size Share by Region (2017-2028)
Figure 39. China Alpha 1 Antitrypsin Deficiency Treatment Market Size YoY Growth (2017-2028) & (US$ Million)
Figure 40. Japan Alpha 1 Antitrypsin Deficiency Treatment Market Size YoY Growth (2017-2028) & (US$ Million)
Figure 41. South Korea Alpha 1 Antitrypsin Deficiency Treatment Market Size YoY Growth (2017-2028) & (US$ Million)
Figure 42. Southeast Asia Alpha 1 Antitrypsin Deficiency Treatment Market Size YoY Growth (2017-2028) & (US$ Million)
Figure 43. India Alpha 1 Antitrypsin Deficiency Treatment Market Size YoY Growth (2017-2028) & (US$ Million)
Figure 44. Australia Alpha 1 Antitrypsin Deficiency Treatment Market Size YoY Growth (2017-2028) & (US$ Million)
Figure 45. Latin America Alpha 1 Antitrypsin Deficiency Treatment Market Size YoY (2017-2028) & (US$ Million)
Figure 46. Latin America Alpha 1 Antitrypsin Deficiency Treatment Market Size Market Share by Indication (2017-2028)
Figure 47. Latin America Alpha 1 Antitrypsin Deficiency Treatment Market Size Market Share by End Users (2017-2028)
Figure 48. Latin America Alpha 1 Antitrypsin Deficiency Treatment Market Size Share by Country (2017-2028)
Figure 49. Mexico Alpha 1 Antitrypsin Deficiency Treatment Market Size YoY Growth (2017-2028) & (US$ Million)
Figure 50. Brazil Alpha 1 Antitrypsin Deficiency Treatment Market Size YoY Growth (2017-2028) & (US$ Million)
Figure 51. Middle East & Africa Alpha 1 Antitrypsin Deficiency Treatment Market Size YoY (2017-2028) & (US$ Million)
Figure 52. Middle East and Africa Alpha 1 Antitrypsin Deficiency Treatment Market Size Market Share by Indication (2017-2028)
Figure 53. Middle East and Africa Alpha 1 Antitrypsin Deficiency Treatment Market Size Market Share by End Users (2017-2028)
Figure 54. Middle East and Africa Alpha 1 Antitrypsin Deficiency Treatment Market Size Share by Country (2017-2028)
Figure 55. Turke
  • 2021-2030 Report on Global Corneal Edema Drugs Market by Player, Region, Type, Application and Sales Channel
    Published: 18-Jan-2022        Price: US 2500 Onwards        Pages: 105
    This report studies the Corneal Edema Drugs market, covering market size for segment by type (Rx Drugs, OTC Drugs, etc.), by application (Hospital & Clinic, Retail Pharmacy, etc.), by sales channel (Direct Channel, Distribution Channel), by player (Bausch + Lomb, Abbott, Clear Eyes, Sager Pharma, ALCON, etc.) and by region (North America, Europe, Asia-Pacific, South America and Middle East & Africa). This report provides detailed historical analysis of global market for Corneal Ed......
  • 2021-2030 Report on Global Veterinary Antifungal Drugs Market by Player, Region, Type, Application and Sales Channel
    Published: 18-Jan-2022        Price: US 2500 Onwards        Pages: 121
    This report studies the Veterinary Antifungal Drugs market, covering market size for segment by type (Oral, Parenteral, etc.), by application (Livestocks, Companion Animals, etc.), by sales channel (Direct Channel, Distribution Channel), by player (Zoetis, Elanco, Boehringer Ingelheim, Merck, Virbac, etc.) and by region (North America, Europe, Asia-Pacific, South America and Middle East & Africa). This report provides detailed historical analysis of global market for Veterinary An......
  • 2021-2030 Report on Global Corneal Edema Treatment Market by Player, Region, Type, Application and Sales Channel
    Published: 18-Jan-2022        Price: US 2500 Onwards        Pages: 107
    This report studies the Corneal Edema Treatment market, covering market size for segment by type (Rx Drugs, OTC Drugs, etc.), by application (Hospital & Clinic, Retail Pharmacy, etc.), by sales channel (Direct Channel, Distribution Channel), by player (Bausch + Lomb, Abbott, Clear Eyes, Sager Pharma, ALCON, etc.) and by region (North America, Europe, Asia-Pacific, South America and Middle East & Africa). This report provides detailed historical analysis of global market for Cornea......
  • 2021-2030 Report on Global Antifungal Drugs for Veterinary Market by Player, Region, Type, Application and Sales Channel
    Published: 18-Jan-2022        Price: US 2500 Onwards        Pages: 118
    This report studies the Antifungal Drugs for Veterinary market, covering market size for segment by type (Oral, Parenteral, etc.), by application (Livestocks, Companion Animals, etc.), by sales channel (Direct Channel, Distribution Channel), by player (Zoetis, Elanco, Boehringer Ingelheim, Merck, Virbac, etc.) and by region (North America, Europe, Asia-Pacific, South America and Middle East & Africa). This report provides detailed historical analysis of global market for Antifunga......
  • 2021-2030 Report on Global Precision Medicine Market by Player, Region, Type, Application and Sales Channel
    Published: 18-Jan-2022        Price: US 2500 Onwards        Pages: 135
    This report studies the Precision Medicine market, covering market size for segment by type (Drug Discovery, Biomarker-Based Test, etc.), by application (Cancer/Oncology, Central Nervous System (CNS), etc.), by sales channel (Direct Channel, Distribution Channel), by player (Johnson & Johnson, Roche, Labcorp, Abbott Laboratories, Novartis, etc.) and by region (North America, Europe, Asia-Pacific, South America and Middle East & Africa). This report provides detailed historical ana......
  • 2021-2030 Report on Global OTC Hair Loss Treatments Market by Player, Region, Type, Application and Sales Channel
    Published: 18-Jan-2022        Price: US 2500 Onwards        Pages: 121
    This report studies the OTC Hair Loss Treatments market, covering market size for segment by type (Minoxidil, Procapil, etc.), by application (Men, Women, etc.), by sales channel (Direct Channel, Distribution Channel), by player (Merck, Johnson & Johnson, Taisho Pharma, Cipla, Bayer, etc.) and by region (North America, Europe, Asia-Pacific, South America and Middle East & Africa). This report provides detailed historical analysis of global market for OTC Hair Loss Treatments from ......
  • 2021-2030 Report on Global Advanced Drug Delivery Market by Player, Region, Type, Application and Sales Channel
    Published: 18-Jan-2022        Price: US 2500 Onwards        Pages: 136
    This report studies the Advanced Drug Delivery market, covering market size for segment by type (Oral, Inhalation, etc.), by application (Hospitals, Diagnostic Centers, etc.), by sales channel (Direct Channel, Distribution Channel), by player (3M, Abbott Laboratories, Allergan, Antares Pharma, Baxter International, etc.) and by region (North America, Europe, Asia-Pacific, South America and Middle East & Africa). This report provides detailed historical analysis of global market fo......
  • 2021-2030 Report on Global Advanced Drug Delivery System Market by Player, Region, Type, Application and Sales Channel
    Published: 18-Jan-2022        Price: US 2500 Onwards        Pages: 130
    This report studies the Advanced Drug Delivery System market, covering market size for segment by type (Oral, Inhalation, etc.), by application (Hospitals, Diagnostic Centers, etc.), by sales channel (Direct Channel, Distribution Channel), by player (3M, Abbott Laboratories, Allergan, Antares Pharma, Baxter International, etc.) and by region (North America, Europe, Asia-Pacific, South America and Middle East & Africa). This report provides detailed historical analysis of global ma......
  • 2021-2030 Report on Global Biopharmaceutical CMO & CRO Market by Player, Region, Type, Application and Sales Channel
    Published: 18-Jan-2022        Price: US 2500 Onwards        Pages: 133
    This report studies the Biopharmaceutical CMO & CRO market, covering market size for segment by type (Contract Manufacturing, Contract Research, etc.), by application (Biologics, Biosimilars, etc.), by sales channel (Direct Channel, Distribution Channel), by player (Boehringer Ingelheim, Lonza, Inno Biologics, Rentschler Biotechnologie, JRS PHARMA, etc.) and by region (North America, Europe, Asia-Pacific, South America and Middle East & Africa). This report provides detailed histo......
  • SERVICES
    Value for Money
    We believe in "optimum utilization of available budget and resources". While servicing our clients' (your) market research requirements, we keep the same approach in focus to help you get the best value for your $$s.
    Ever Growing Inventory
    Ranging from the smallest feasible / required data (datasheets, data facts, SWOT analysis, company profiles, etc) to full research reports that help you make decisions, our inventory is updated almost on a daily basis with the latest industry reports from domain experts that track more than 5000 niche sectors.
    One Stop Solution
    Need a custom research report on medical devices market? Require all available business intelligence on 3D printing industry? Exploring F&B sector of a particular country/region? RnRMarketResearch.com is your one-stop-solution to all market intelligence needs. We not only offer custom research and consulting services, we also "bundle" reports to meet your needs and help you fetch the data analysis you require for your business.
    Dedicated Client Engagement
    Not limited to only "finding" relevant reports for you, our client engagement team dedicates its efforts to understand your "business need" and accordingly maps available research data to help you move forward. Call "your" client engagement executive any time of your day and get your questions answered in order to make the correct business decision.
    Saving Time and Efforts
    Simply share your research requirement details with us and let us do all the hard work to find required intelligence for you. When you add up our "one stop solution" and "dedicated client engagement" services mentioned above, you obviously know the time and effort saving you do by working with us.
    Payment Flexibility
    Working with Fortune 500 organizations, we understand the importance of being flexible for payments. Share your payment terms with us and we will surely match up to them to ensure you get access to required business intelligence data without having to wait for the payment to be done.
    Post-Purchase Research Support
    Have questions after reading a report / datasheet bought through us? Not sure about the methodology used for data available in the research? Talk to us / Share your questions with us and if required, we will connect you with the analyst(s)/author(s) of the report(s) and ensure you get satisfactory answers for the same. Need more data / analysis / report(s) on the topic of your research/project? The RnRMarketResearch.com team is here for you 24X7 to support you with your post-purchase requirements. Subscription Offers & Packages (Get in touch with us for more details - [email protected] / +1 888 391 5441 )
    • Ad Hoc
    • Pay - as - you - go / Bucket Subscriptions
    • Fixed Cost for #of reports
    • Customize / Personalize as per your needs